AZN analyst estimates
AstraZeneca (AZN) analyst ratings, the average price target and its range, and every firm's latest call.
AZN analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Dec 10, 2025 | HSBC | AstraZeneca price target raised to $108 from $95 at HSBC | $108.00 |
| Dec 3, 2025 | Morgan Stanley | AstraZeneca price target raised to $103 from $93 at Morgan Stanley | $103.00 |
| Jul 9, 2025 | Berenberg Bank | AstraZeneca price target raised to $97 from $93 at Berenberg | $97.00 |
| Nov 13, 2024 | BMO Capital | AstraZeneca (AZN) PT Lowered to $88 at BMO Capital | $88.00 |
| Sep 11, 2024 | BMO Capital | BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN) | $89.00 |
| May 30, 2024 | Argus Research | AstraZeneca (AZN) PT Raised to $85 at Argus | $85.00 |
| May 28, 2024 | BMO Capital | BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN) | $82.00 |
| Jul 12, 2023 | Leerink Partners | These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts | $79.00 |
| Jan 5, 2023 | BMO Capital | BMO Capital Initiates Coverage On AstraZeneca with Outperform Rating, Announces Price Target of $82 | $82.00 |
| Nov 11, 2022 | Leerink Partners | SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $78 | $78.00 |
| May 4, 2022 | Leerink Partners | SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $75 | $75.00 |
- 6 firms rate AZN: 5 buy, 0 hold, 1 sell.
Updated 2026-11-02 18:26 UTC